Investors pile on Stanford spinout promising new ways to attack cancer, autoimmune diseases

Inflammation-signaling cytokines are infamously tough to control. Here's why this startup thinks it can harness their potential — and top-drawer investors have now ponied up close to $200 million over two years.
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news